The company is now celebrating a decade working on the design and manufacture of novel microfluidic products for our customers; we are proud and delighted to have made it this far, and excited about the future!
During this time, we´ve grown in many ways, for example by increasing the number of employees and clients, as well as boosting revenues. We have collaborated successfully in more than 300 microfluidic projects around the world, doubling our turnover since 2014 and we have gained vast experience in this business dimension. In addition, we develop new value propositions to our customers, offering unique complete value chain solutions from complex microfluidic consumables that can be processed on our own design automated instrumentation (e.g. Point of Care instruments).
Since its establishment, microLIQUID has focused on delivering quality to its customers and fulfilling their expectations. This is the reason why so many of our clients and partners trust our professionalism and appreciate the individual approach we provide.
We are grateful to all those who have worked with us and have helped us over these last 10 years to develop our company. microLIQUID´s success would not have come to fruition had it not been for their unwavering support.
We are optimistic about what lies ahead and are very confident that we will be able to help many more future customers around the world to manufacture solutions based on our microfluidics and automated instrument solutions in fields such as rapid testing, immuno-oncology, NGS and Precision medicine, liquid biopsy and drug delivery among others.
microLIQUID has shown once again that it strives to develop new point-of-care platforms by using the latest technologies in microfluidics.
In this project, microLIQUID will be working together with European leaders, both from academia and industry, to develop new PoC applications.
We invite you to read the press release issued by Ghent University at the start of the project in October 2017.
“Ghent, Belgium – October 1, 2017 – Ghent University and its project partners today announced the launch of the PoCOsteo project. Together they will develop and validate a point-of-care in-office device for identifying individuals at high risk of osteoporosis and osteoporotic fracture. The project is supported by the European Union’s Horizon 2020 Framework Programme for Industrial leadership in nanotechnologies, advanced materials, biotechnology and advanced manufacturing and processing (H2020-NMBP). The overall goal of the project is the development, clinical validation and preparation for commercialisation of a point-of-care tool for bone disease (a.o. osteoporosis) prevention, detection and treatment.
Indeed, as a consequence of the ageing of the society, osteoporosis (literally “porous bone”) and its complications is becoming more and more prevalent, making the bone disease a health priority in many parts of the world. Usually osteoporosis manifests itself in a drastic manner, i.e. through fracture of the osteoporotic bone in the affected individual. This causes a serious burden for the patient and a high medical care cost for the society. Currently osteoporosis is commonly known as a “silent killer” disease. Up to 20% of patients die in the first year following a hip fracture, mostly due to pre-existing medical conditions. Less than half of those who survive the hip fracture regain their previous level of function1. Early detection of individuals at risk of osteoporosis and starting a suitable treatment before fractures and complications arise would drastically improve the current situation. Until now little or no measures for prevention or early detection of osteoporosis are taken, because no simple, yet sufficiently accurate or sensitive tools for early detection are available.
The PoCOsteo system will employ electrochemical detection and brings together proteomics, genomics and microfluidics technologies. The in-office test will provide the results in real-time during consultation and can be performed by unskilled technicians even at rural areas where access to current state-of-the-art equipment is limited. The design will limit the amount of both expensive reagents and blood samples needed for the tests and so it not only reduces the cost of each test, which is of great importance, especially nowadays when full reimbursement is not practiced in many countries, but also reduces the patient’s pain and discomfort.
The project will be supported and advised by the IOF, the International Osteoporosis Foundation, which is the main global alliance of patient societies, research organizations, healthcare professionals and international companies working to promote bone, muscle and joint health.
Over the next four years, PoCOsteo will be coordinated by Ghent University. Industrial, academic and clinical partners will bring their expertise to the project: Universitat Rovira I Virgili and microLIQUID (Spain), Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung (Germany), Labman Automation (United Kingdom), Medizinische Universität Graz (Austria), Endocrinology and Metabolism Research Institute (Iran) and Fundico (Belgium).”